GTBP: GT Biopharma, Inc. Stock

by  •  • Comments Off on GTBP: GT Biopharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.03
Enterprise Value ($M) -1.39
Book Value ($M) 2.10
Book Value / Share 0.94
Price / Book 2.40
NCAV ($M) 2.10
NCAV / Share 0.94
Price / NCAV 2.40

Profitability (mra)
Return on Invested Capital (ROIC) -5.89
Return on Assets (ROA) -0.88
Return on Equity (ROE) -1.65

Liquidity (mrq)
Quick Ratio 1.45
Current Ratio 1.45

Balance Sheet (mrq) ($M)
Current Assets 6.76
Assets 6.76
Liabilities 4.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
10-17 13G/A Cytovance Biologics Inc
05-23 13G/A Bristol Investment Fund Ltd 8.80 -41.56
02-14 13G/A Armistice Capital, Llc 4.99 -40.83

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 5,389 24,883 21.66
2025-02-03 8,570 33,996 25.21
2025-01-31 10,064 20,723 48.56
2025-01-30 13,919 30,259 46.00

(click for more detail)

Similar Companies
GNPX – Genprex, Inc. GOVX – GeoVax Labs, Inc.
GRCE – Grace Therapeutics, Inc. GYRE – Gyre Therapeutics, Inc.
HEPA – Hepion Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io